Overview

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
beta-Lactams
Ceftriaxone
Lactams